Ontology highlight
ABSTRACT:
SUBMITTER: Jain N
PROVIDER: S-EPMC4310865 | biostudies-literature | 2014 Jan
REPOSITORIES: biostudies-literature
Jain Nitin N Curran Emily E Iyengar Neil M NM Diaz-Flores Ernesto E Kunnavakkam Rangesh R Popplewell Leslie L Kirschbaum Mark H MH Karrison Theodore T Erba Harry P HP Green Margaret M Poire Xavier X Koval Greg G Shannon Kevin K Reddy Poluru L PL Joseph Loren L Atallah Ehab L EL Dy Philip P Thomas Sachdev P SP Smith Scott E SE Doyle L Austin LA Stadler Walter M WM Larson Richard A RA Stock Wendy W Odenike Olatoyosi O
Clinical cancer research : an official journal of the American Association for Cancer Research 20131031 2
<h4>Purpose</h4>The clinical relevance of targeting the RAS/RAF/MEK/ERK pathway, activated in 70% to 80% of patients with acute myelogenous leukemia (AML), is unknown.<h4>Experimental design</h4>Selumetinib is an oral small-molecule inhibitor of MAP-ERK kinase (MEK)-1/2. Forty-seven patients with relapsed/refractory AML or 60 years old or more with untreated AML were enrolled on a phase II study. Patients were stratified by FLT3 ITD mutation status. The primary endpoint was response rate (comple ...[more]